Analysts Set MDxHealth SA (NASDAQ:MDXH) Price Target at $3.50

MDxHealth SA (NASDAQ:MDXH) has been assigned an average rating of “Hold” from the five brokerages that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $3.50.

A number of equities analysts recently commented on the stock. Wall Street Zen lowered shares of MDxHealth from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. BTIG Research decreased their target price on shares of MDxHealth from $7.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, May 14th. William Blair cut shares of MDxHealth from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Lake Street Capital lowered their target price on shares of MDxHealth from $9.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, May 14th. Finally, TD Cowen reiterated a “buy” rating and issued a $1.50 price target (down from $7.00) on shares of MDxHealth in a research report on Thursday, May 14th.

Hedge Funds Weigh In On MDxHealth

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jefferies Financial Group Inc. bought a new stake in shares of MDxHealth during the 3rd quarter valued at $53,000. Russell Investments Group Ltd. bought a new position in shares of MDxHealth in the third quarter worth $461,000. Kennedy Capital Management LLC bought a new position in shares of MDxHealth in the third quarter worth $1,826,000. Panoramic Capital LLC acquired a new position in MDxHealth in the third quarter valued at about $721,000. Finally, Bank of America Corp DE raised its stake in MDxHealth by 5,164.0% in the third quarter. Bank of America Corp DE now owns 15,055 shares of the company’s stock valued at $70,000 after purchasing an additional 14,769 shares in the last quarter.

MDxHealth Price Performance

MDXH opened at $0.42 on Tuesday. The business has a fifty day simple moving average of $0.57 and a 200 day simple moving average of $2.12. The company has a market capitalization of $20.90 million, a PE ratio of -0.65 and a beta of 1.43. MDxHealth has a 1 year low of $0.40 and a 1 year high of $5.33.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The business had revenue of $23.90 million during the quarter, compared to analysts’ expectations of $30.89 million. Equities analysts anticipate that MDxHealth will post -0.6 earnings per share for the current fiscal year.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.